Summary: A systematic meta-analysis of gene expression studies in humans and rodents identifies key biological pathways linked to response to the SSRI fluoxetine. The work highlights immune-related networks—especially toll-like receptor signaling—and neural signal transduction mechanisms that distinguish responders from non-responders, while also revealing consistent changes in protein metabolism and GABAergic signaling following treatment.
These findings emphasize the biological complexity of antidepressant response and point to molecular pathways that could inform future efforts in precision psychiatry and biomarker development.
Key Facts:
- Immune Pathways: Toll-like receptor and NF-κB–related pathways were consistently implicated in differences between responders and non-responders.
- Neural Mechanisms: Signal transduction, neurotrophic signaling (including BDNF-related pathways), and GABAergic synapse pathways were repeatedly altered with fluoxetine treatment.
- Heterogeneity: Gene expression patterns varied across tissues, experimental models, sexes and individuals, underscoring the need for larger, better-balanced studies.
Source: Neuroscience News
Why do some people respond to antidepressants while others do not? This persistent clinical question motivates efforts to understand molecular predictors and mechanisms of antidepressant efficacy. Major depressive disorder (MDD) remains a leading cause of disability worldwide, and about half of patients do not achieve remission with their first prescribed antidepressant. Identifying the biological drivers of response or resistance is therefore essential for improving outcomes.
This meta-analysis synthesizes gene expression data from both human patients and rodent models treated with fluoxetine (Prozac), seeking consistent transcriptomic signatures associated with treatment and with behavioral or clinical response. By reanalyzing multiple datasets through a single pipeline, the authors aimed to reveal reproducible pathway-level changes that individual studies, limited by sample size and methodological variability, might miss.
A Complex Puzzle: Why Study Gene Expression?
Selective serotonin reuptake inhibitors (SSRIs) like fluoxetine have long been prescribed for depression, but their full mechanisms of action extend beyond monoamine modulation. Contemporary evidence implicates neuroplasticity, inflammation, and broad cellular signaling networks in antidepressant effects. Transcriptomic approaches allow investigators to profile these changes at the gene and pathway level, and meta-analysis helps separate consistent signals from study-specific noise.
Following PRISMA guidelines, the researchers searched the Gene Expression Omnibus (GEO) for studies profiling gene expression in the context of fluoxetine treatment in depression- and anxiety-related settings. They reanalyzed included datasets for differential expression and performed gene set enrichment analyses to identify pathways consistently altered across studies.
What They Found: Pathways That Matter
From 74 screened datasets, 20 met inclusion criteria: 18 rodent studies and two human studies. Datasets covered both brain and peripheral tissues and varied widely in design, stress paradigms, and sample composition, producing substantial heterogeneity. Despite this, meta-analyses uncovered robust, reproducible trends.
When comparing responders versus non-responders across six datasets, 18 biological pathways were consistently enriched among good responders. Immune pathways—particularly toll-like receptor (TLR) signaling and NF-κB activation—featured prominently. Intriguingly, immune-related signals were upregulated in blood samples from non-responders yet modestly elevated in brain tissues of responders, suggesting peripheral and central immune responses may diverge.
Protein metabolism pathways, including ribosomal subunit pathways, were more consistently associated with non-response. Ribosomal proteins have prior links to both immune regulation and antidepressant resistance, supporting these observations.
Across treatment comparisons (fluoxetine versus control), 17 pathways consistently changed. GPCR signaling and GABAergic synapse pathways tended toward downregulation after treatment, while signal transduction pathways and neurotrophic factors such as BDNF showed upregulation—consistent with hypotheses that fluoxetine promotes neuroplastic adaptations.
Why Immune Pathways?
The repeated involvement of immune-related pathways fits a growing body of evidence connecting inflammation and depression. Elevated pro-inflammatory cytokines characterize subgroups of people with MDD, and anti-inflammatory interventions have shown some benefit in treatment-resistant cases. Experimental models implicate TLR signaling in stress-induced neuroinflammation and depressive-like behaviors; inhibiting TLR2 or TLR4 reduces neuroinflammation and improves outcomes in rodents, supporting a potential role for excessive innate immune activation in treatment resistance.
The contrast between peripheral and central immune signatures suggests that blood-based biomarkers might not fully mirror central nervous system processes, although peripheral measures could still provide useful, accessible predictors if interpreted carefully.
Signal Transduction and Neuroplasticity
Beyond immunity, the meta-analysis reinforces the role of signal transduction and neuroplasticity in antidepressant response. Fluoxetine’s capacity to increase BDNF expression and promote hippocampal neurogenesis aligns with observed upregulation of neurotrophic and signaling pathways. The consistent downregulation of GABAergic signaling after treatment indicates a shift in excitatory–inhibitory balance that may accompany plastic changes important for symptom improvement.
Strengths, Limitations, and the Road Ahead
This work is among the first systematic meta-analyses to combine treatment and response signatures for an antidepressant across species and tissues using a unified reanalysis approach. That strategy improved consistency and highlighted pathways that recur across diverse studies.
However, important limitations remain. Only two human datasets were available, both small and skewed toward female participants, while most rodent studies used male animals. Larger, sex-balanced human cohorts and integrated multi-omics approaches will be essential to validate and extend these findings. The heterogeneity between blood and brain results also points to the complexity of translating peripheral biomarkers into markers of central processes.
Toward Precision Psychiatry
Overall, the results support a model in which antidepressant response emerges from interacting networks—immune signaling, neurotrophic support and signal transduction—rather than from a single gene. These pathways provide candidate targets for developing predictive biomarkers and for testing combined therapeutic strategies that address both neurotransmitter and immune dysregulation. Better understanding how stress, inflammation and neuroplasticity interact could guide more personalized treatments for depression.
Conclusion
Depression and its treatment are biologically multifaceted. This meta-analysis identifies reproducible transcriptomic signatures of fluoxetine treatment and response, highlighting immune and signal transduction pathways as central elements. These insights offer a clearer map for future research and a foundation for developing more targeted, effective interventions.
Abstract
Gene expression signatures of response to fluoxetine treatment: systematic review and meta-analyses
Background
Genomic and other omics data have illuminated pharmacological signatures of antidepressant response, but individual studies often disagree. This work synthesizes gene expression data from fluoxetine-treated human samples and rodent models to identify biological pathways affected by treatment and those that distinguish responders from non-responders.
Methods
Following PRISMA guidelines, the authors searched the Gene Expression Omnibus for relevant fluoxetine studies in humans and rodents, excluding studies outside depression or anxiety contexts, those using irrelevant tissues, or groups with fewer than three samples. Included studies were reanalyzed by differential expression and Gene Set Enrichment Analysis (GSEA). Pathway and gene-level statistics were combined across studies using multiple p-value combination methods and corrected for false discovery.
Results
Of 74 datasets screened, 20 met inclusion criteria (18 rodent, two human). Heterogeneity was substantial, but 18 pathways were consistently different between responders and non-responders—including TLR and other immune pathways—and signal transduction pathways were consistently affected by fluoxetine across models.
Discussion
These meta-analyses confirm known pathways and suggest new leads toward understanding antidepressant resistance. Still, more large, well-powered human studies and additional omics data are needed to resolve heterogeneity and translate these findings into clinical biomarkers and novel therapies.
Author: Neuroscience News Communications
Source: Neuroscience News
Contact: Neuroscience News Communications
Image: The image is credited to Neuroscience News
Source: Open access. “Gene expression signatures of response to fluoxetine treatment: systematic review and meta-analyses” by David G. Cooper et al., Molecular Psychiatry